Finanzen von Evogene Ltd (EVGN)EVGNEvogene Ltd

Evogene Ltd (EVGN) generates its revenue primarily from Agricultural Crops, which accounts for 100.0% of total sales, equivalent to $4.41M. Understanding this concentration is critical for investors evaluating how EVGN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Evogene Ltd maintains a gross margin of 40.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -606.63%, while the net margin is -363.40%. These profitability ratios, combined with a Return on Equity (ROE) of -6267.84%, provide a clear picture of how effectively EVGN converts its operational activities into shareholder value.

In the context of the broader market, EVGN competes directly with industry leaders such as SNTI and IMNN. With a market capitalization of $4.45M, it holds a significant position in the sector. When comparing efficiency, EVGN's gross margin of 40.63% stands against SNTI's 100.00% and IMNN's N/A. Such benchmarking helps identify whether Evogene Ltd is trading at a premium or discount relative to its financial performance.

Evogene's financial performance shows a troubling trend with a net loss of $1.8 million in Q2 2026, despite a 62% improvement from the previous year. The gross margin has fluctuated significantly, with the latest at 40.63%, indicating challenges in maintaining profitability. The company has also seen a drastic drop in revenue, totaling only $0.7 million in the first half of 2026, down from $2.9 million in 2025.